Extensive Stage Small Cell Lung Cancer Market Size is predicted exhibit a 7.4% CAGR during the forecast period for 2023-2031.
Small cell lung cancer (SCLC ) is a kind of cancer that affects lung tissue. SCLC has two stages limited and extensive stage. Extensive stage small cell lung cancer (SCLC) proliferates throughout one lung, both lungs or other body parts, making it difficult to treat. There is no complete cure treatment available for extensive-stage SCLC. However, chemotherapy, radiation therapy, and other treatments can be used to maintain the quality of patients' life, improve symptoms, and prolong life.
Recent advanced studies in the molecular biology of SCLC may open up opportunities for molecularly informed therapeutic strategies for patients with SCLC, which could significantly improve the outcome of this disease.
Market Trends:
- Developing combination treatments to get effective and safe therapies for patients with vast-stage SCLC is expected to increase the growth opportunities of the expansive stage small cell lung cancer market in the upcoming years.
- Focusing on research and development activities of companies involved in manufacturing extensive stage small cell lung cancer treatments and collaborating or partnerships with the companies involved in discovering cancer therapies.
- Introducing immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment is also driving the market growth.
Competitive Landscape:
Global Extensive Stage Small Cell Lung Cancer Market Players:
- Hoffmann-La Roche Ltd
- AstraZeneca PLC
- Jazz Pharmaceuticals Plc
- G1 Therapeutics Inc.
- Shanghai Henlius Biotech, Inc.
- Lee's Pharmaceutical Limited
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Beigene Ltd.
Significant competitors in the global market for extensive-stage small-cell lung cancer are always looking for cooperation opportunities to improve their market positions and increase their market penetration. The information is published after thorough research, analysis of market trends, significant events, fresh initiatives, and technological advancements and innovations. The report examines various market participants in the industry. The major corporations are employing multiple methods, including alliances, mergers, acquisitions, and others, which are further anticipated to accelerate market expansion and increase their market presence and share.
Recent Developments:
- In January 2023, Fosun Pharma joined into an exclusive license agreement with Shanghai Henlius Biotech, Inc. to commercialize Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (U.S.).
- In November 2019, AstraZeneca obtained a supplemental Biologics License Application (sBLA) from the U.S. Food and Drug Administration (FDA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).
Market Drivers:
Increasing Prevalence Of Extensive Stage Small Cell Lung Cancer
The increasing prevalence of extensive stage small cell lung cancer is expected to expand the demand for the market during the forecast period. For instance, according to the American Cancer Society (ACS), Lung cancer (both small cell and non-small cell) is the second most expected cancer in the United States. In 2023, there will be 238,340 new cases of lung cancer and around 127,070 deaths from lung cancer.
Addressing The Toxic Effects Of Chemotherapies To Maximize The Therapeutic Potential Of Cancer Treatments
Introducing checkpoint inhibitors in the extensive stage of small cell lung cancer therapies can improve the safety and effectiveness of the treatment, which will help maximize the therapeutic potential of cancer treatments. Hence, the introduction of checkpoint inhibitors is anticipated to accelerate the market growth opportunities in the upcoming future.
Restraints:
Toxic Effects Of Treatment
The side effects associated with chemotherapies and limitations related to cancer therapies & drugs are expected to impede the market expansion during the forecast period. In addition, the high cost of medicines and treatments is also going to hinder market expansion.
Market Segmentation:
The global Extensive Stage Small Cell Lung Cancer Market is segregated based on product and region. Based on product, the market segmentation is divided into commercial and clinical. The clinical segment is anticipated to dominate the market soon. According to the WHO, cancer cases will rise to 29.4 million by 2040, which is expected to boost the need for advanced cancer treatments, thereby surging the market demand over the projected period.
Regional Landscape: North America Holds A Significant Regional Revenue Share
North America region is anticipated to lead the global extensive-stage small cell lung cancer market over the forecast period. The growth is attributed to the presence of developed healthcare infrastructure and permitted reimbursement policies for medical treatments. Furthermore, the rising prevalence of extensive-stage small lung cancer is estimated to drive the North American market during the projected period.
The Asia-Pacific region is anticipated to hold the maximum share of the market in the near future. The high prevalence of cancers and unmet medical needs will likely drive new growth opportunities for market players in this region. In addition, R&D efforts for manufacturing effective therapies and rising government initiatives in developing to improve public awareness regarding cancer diseases are expected to propel further the extensive stage small cell lung cancer market.
Extensive Stage Small Cell Lung Cancer Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 7.4 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product and Region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Jazz Pharmaceuticals Plc, G1 Therapeutics Inc., Lee's Pharmaceutical Limited, Shanghai Henlius Biotech, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beigene Ltd. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
